NASA’s COVID-19 ventilator gains FDA approval for emergency use
The Food and Drug Administration for emergency use a ventilator specially developed by the National Aeronautics and Space Administration to treat COVID-19 patients.
NASA’s VITAL (Ventilator Intervention Technology Accessible Locally) system is designed to last three to four months and is specifically tailored for patients with COVID-19 by providing respiratory support for patients experiencing respiratory failure or insufficiency.
Additionally, the device is designed to be built with components outside the current medical device supply chain and thereby will not impact existing ventilator supply chains.
Related News Articles
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…
Headline
The Senate Finance Committee Feb. 4 voted 14-13 to advance Robert F. Kennedy Jr.’s nomination for secretary of the Department of Health and Human Services. A…
Headline
Respiratory illness activity remains high across the country, according to the latest data from the Centers for Disease Control and Prevention. Seasonal flu…
Headline
The Occupational Safety and Health Administration Jan. 13 announced that it terminated efforts to establish a final COVID-19 safety standard to protect workers…
Headline
The Department of Health and Human Services Dec. 10 amended the Public Readiness and Emergency Preparedness Act declaration for COVID-19, extending liability…
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…